Alamar Biosciences is growing revenue 99% YoY as an industry leader, but the stock has already reached its prior analyst target with a failed asymmetry gate, a momentum score sitting exactly at the pass-fail line, and an expensive, leverage-penalized valuation, leaving little room for further re-rating.
Thesis pillars
- Elite Revenue Growth Industry Leader→Stable
- Target Already Reached→Stable
- Failed Asymmetry At Momentum Floor→Stable
- +1 more pillar — see the Why tab for full reasoning
Alamar Biosciences, Inc. (ALMR) Stock Analysis
Healthcare · Medical Devices
Hold if already holding. Not a fresh buy at $24.24, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8); Negative momentum.
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein... Read more
Hold if already holding. Not a fresh buy at $24.24, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8); Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Score 6.1/10, moderate confidence.
Passes 7/8 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, earnings proximity 22d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent developments
updated 2026-10-13Recent Developments — Alamar Biosciences, Inc.
Latest news
- NEWS Analysts Offer Insights on NA Companies: Alamar Biosciences, Inc. (ALMR), NIQ Global Intelligence PLC (NIQ) and Amentum — The Globe and Mail neutral
- NEWS Biotech Stocks At 52-Week Highs - ALMR +30% On Q2 Reports, DYN, CGEM, DXCM, CAH - RTTNews — RTTNews positive
- NEWS ALMR SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus — GuruFocus neutral
- NEWS Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript - AOL.com — AOL.com neutral
- NEWS Alamar Biosciences Shares (ALMR) Surge 31% as Consumables Drive Gross Margin Up - TechStock² — TechStock² positive
Generated 2026-10-13T11:32:14Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
1 floor-breaker·1 ceiling hit
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $24.24, but acceptable to hold if already in. Reasons: V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8); Negative momentum. Chart setup: No clear chart pattern; technical signals are mixed. Mixed signals. Hold existing position. Target $30.80 (+27.1%), stop $22.86 (−6.0%), A.R:R 1.8:1. Score 6.1/10, moderate confidence.
Take-profit target: $30.80 (+27.1% upside). Target $30.80 (+27.1%), stop $22.86 (−6.0%), A.R:R 1.8:1. Stop-loss: $22.86.
V7 low-quality RISK_OFF penalty: -0.5 (Q=4.8); Negative momentum.
Alamar Biosciences, Inc. trades at a P/E of N/A (forward -46.6). TrendMatrix value score: 5.4/10. Verdict: Hold.
11 analysts cover ALMR with a consensus score of 4.2/5. Average price target: $35.
What does Alamar Biosciences, Inc. do?Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments,...
Alamar Biosciences, Inc., a proteomics company, develops a proteomic liquid biopsy platform and sells instruments, consumables, and services to early detection of diseases. The company develops NULISA technology, a proteomics platform that detects and quantifies protein biomarkers. It offers ARGO high throughput (HT) System, a fully automated precision proteomics platform, performs ultra-high sensitivity and multiplexed analysis to support biomarker analysis across the continuum of discovery, translational research and ultimately, and diagnostics. The company's offering is utilized in research areas including immunology, neurology, and oncology. It serves global research and academic institutions, biopharmaceutical companies, contract research organizations, and service labs. The company operates in the United States, rest of Europe, Middle East and Africa, Germany, Asia Pacific, and internationally. It has a strategic partnership with Alzheimer's Disease Data Initiative, and Gates Ventures to advance translational research in alzheimer's disease. The company was incorporated in 2018 and is based in Fremont, California.